SODIUM MECLOFENAMATE (MECLOMEN) IN THE TREATMENT OF JUVENILE RHEUMATOID-ARTHRITIS - A SEGMENT-I STUDY

  • 1 January 1982
    • journal article
    • research article
    • Vol. 9  (1) , 129-134
Abstract
Patients [39] with juvenile rheumatoid arthritis were treated with sodium meclofenamate (Meclomen) during a 4-wk open-labeled, noncontrolled trial. Increasing doses started at 3 mg/kg per day, 4 times/day, up to 7.5 mg/kg per day, not to exceed 300 mg/day. Seven patients dropped out due to adverse side effects and 1 from inefficacy. Efficacy analysis showed statistically significant decreases in several disease indices, in particular the duration of morning stiffness. Twenty-one patients who completed the 4-wk study entered an extended open-labeled study. Nine patients completed at least 9 mo. of sodium meclofenamate therapy. At 9 mo., these 19 showed mean decreases in all rheumatologic disease indices measured. The drug was approved by the Food and Drug Administration [USA] for use in adults.